[Refractory cutaneous leishmaniasis: Benefit of miltefosine].

[Refractory cutaneous leishmaniasis: Benefit of miltefosine]. Med Mal Infect. 2018 Dec 13;: Authors: Guerveno C, Delavigne K, Berry A, Martin-Blondel G, Delobel P PMID: 30554949 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30554949?dopt=Abstract

Source: Medecine et Maladies Infectieuses - December 19, 2018 Category: Infectious Diseases Tags: Med Mal Infect Source Type: research

More News: Infectious Diseases